
Statin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Description
Statin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Market Overview:
The global statin market size reached US$ 14.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 18.1 Billion by 2028, exhibiting a growth rate (CAGR) of 3.2% during 2023-2028.
Statin is a lipid-lowering medication, an agent that is consumed by patients to reduce their blood cholesterol levels. Atorvastatin, rosuvastatin, lovastatin and simvastatin are the most common types of statins available in the market. They aid in preventing the instances of atherosclerosis and heart attacks and have significant anti-inflammatory and plaque-stabilizing effects. These drugs also aid in minimizing vascular inflammation and oxidative stress in the body. Besides this, statin interferes with the production of enzymes that are crucial for the liver to produce cholesterol, thus aiding in lowering the overall blood cholesterol levels in the body.
The increasing prevalence of hypercholesterolemia across the globe is among the key factors driving the growth of the market. This disorder is highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, obesity and cardiovascular diseases (CVDs), which is facilitating product adoption across both the developed and emerging nations. Furthermore, increasing consumer preference for over-the-counter (OTC) drugs is another factor contributing to the market growth. In comparison to brand name drugs, OTC variants are usually more affordable. Additionally, the growing adoption of combination therapies that use statin with other cholesterol diminishing compounds, such as ezetimibe, is acting as another growth-inducing factor. Research has found statin-ezetimibe combination therapy to be capable of achieving near-normal lipid profiles in familial hypercholesterolemia patients and significantly reducing the risk of CVDs occurrence. Other factors, including improving healthcare infrastructure and growing health consciousness among consumers, are projected to drive the market further.
IMARC Group’s latest report provides a deep insight into the global statin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the statin industry in any manner.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global statin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapeutic area, drug class, application and distribution.
Breakup by Type:
Synthetic Statins
Natural Statins
Breakup by Therapeutic Area:
Cardiovascular Disorders
Obesity
Inflammatory Disorders
Others
Breakup by Drug Class:
Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Simvastatin
Others
Breakup by Application:
Dyslipidemia
Others
Breakup by Distribution:
Hospitals
Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Biocon, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, etc.
Key Questions Answered in This Report:
How has the global statin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global statin market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the therapeutic area?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the market?
What is the structure of the global statin market and who are the key players?
What is the degree of competition in the market?
Market Overview:
The global statin market size reached US$ 14.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 18.1 Billion by 2028, exhibiting a growth rate (CAGR) of 3.2% during 2023-2028.
Statin is a lipid-lowering medication, an agent that is consumed by patients to reduce their blood cholesterol levels. Atorvastatin, rosuvastatin, lovastatin and simvastatin are the most common types of statins available in the market. They aid in preventing the instances of atherosclerosis and heart attacks and have significant anti-inflammatory and plaque-stabilizing effects. These drugs also aid in minimizing vascular inflammation and oxidative stress in the body. Besides this, statin interferes with the production of enzymes that are crucial for the liver to produce cholesterol, thus aiding in lowering the overall blood cholesterol levels in the body.
The increasing prevalence of hypercholesterolemia across the globe is among the key factors driving the growth of the market. This disorder is highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, obesity and cardiovascular diseases (CVDs), which is facilitating product adoption across both the developed and emerging nations. Furthermore, increasing consumer preference for over-the-counter (OTC) drugs is another factor contributing to the market growth. In comparison to brand name drugs, OTC variants are usually more affordable. Additionally, the growing adoption of combination therapies that use statin with other cholesterol diminishing compounds, such as ezetimibe, is acting as another growth-inducing factor. Research has found statin-ezetimibe combination therapy to be capable of achieving near-normal lipid profiles in familial hypercholesterolemia patients and significantly reducing the risk of CVDs occurrence. Other factors, including improving healthcare infrastructure and growing health consciousness among consumers, are projected to drive the market further.
IMARC Group’s latest report provides a deep insight into the global statin market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the statin industry in any manner.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global statin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapeutic area, drug class, application and distribution.
Breakup by Type:
Synthetic Statins
Natural Statins
Breakup by Therapeutic Area:
Cardiovascular Disorders
Obesity
Inflammatory Disorders
Others
Breakup by Drug Class:
Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Simvastatin
Others
Breakup by Application:
Dyslipidemia
Others
Breakup by Distribution:
Hospitals
Clinics
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Biocon, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, etc.
Key Questions Answered in This Report:
How has the global statin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global statin market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the therapeutic area?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the market?
What is the structure of the global statin market and who are the key players?
What is the degree of competition in the market?
Table of Contents
147 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Statin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Type
- 6.1 Synthetic Statins
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Natural Statins
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 7 Market Breakup by Therapeutic Area
- 7.1 Cardiovascular Disorders
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Obesity
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Inflammatory Disorders
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 8 Market Breakup by Drug Class
- 8.1 Atorvastatin
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Fluvastatin
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Lovastatin
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Pravastatin
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Simvastatin
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 9 Market Breakup by Application
- 9.1 Dyslipidemia
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Others
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 10 Market Breakup by Distribution
- 10.1 Hospitals
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
- 10.2 Clinics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
- 10.3 Others
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
- 11 Market Breakup by Region
- 11.1 North America
- 11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
- 11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
- 11.2 Europe
- 11.2.1 Germany
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
- 11.2.2 France
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
- 11.2.3 United Kingdom
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
- 11.2.4 Italy
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
- 11.2.5 Spain
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
- 11.2.6 Russia
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
- 11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
- 11.3 Asia Pacific
- 11.3.1 China
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
- 11.3.2 Japan
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
- 11.3.3 India
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
- 11.3.4 South Korea
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
- 11.3.5 Australia
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
- 11.3.6 Indonesia
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
- 11.3.7 Others
- 11.3.7.1 Market Trends
- 11.3.7.2 Market Forecast
- 11.4 Latin America
- 11.4.1 Brazil
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
- 11.4.2 Mexico
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
- 11.4.3 Others
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast
- 12 SWOT Analysis
- 12.1 Overview
- 12.2 Strengths
- 12.3 Weaknesses
- 12.4 Opportunities
- 12.5 Threats
- 13 Value Chain Analysis
- 14 Porters Five Forces Analysis
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
- 15 Price Indicators
- 16 Competitive Landscape
- 16.1 Market Structure
- 16.2 Key Players
- 16.3 Profiles of Key Players
- 16.3.1 Abbott
- 16.3.1.1 Company Overview
- 16.3.1.2 Product Portfolio
- 16.3.1.3 Financials
- 16.3.1.4 SWOT Analysis
- 16.3.2 AstraZeneca
- 16.3.2.1 Company Overview
- 16.3.2.2 Product Portfolio
- 16.3.2.3 Financials
- 16.3.2.4 SWOT Analysis
- 16.3.3 Aurobindo Pharma
- 16.3.3.1 Company Overview
- 16.3.3.2 Product Portfolio
- 16.3.3.3 Financials
- 16.3.4 Biocon
- 16.3.4.1 Company Overview
- 16.3.4.2 Product Portfolio
- 16.3.4.3 Financials
- 16.3.4.4 SWOT Analysis
- 16.3.5 GlaxoSmithKline
- 16.3.5.1 Company Overview
- 16.3.5.2 Product Portfolio
- 16.3.5.3 Financials
- 16.3.5.4 SWOT Analysis
- 16.3.6 Merck & Co.
- 16.3.6.1 Company Overview
- 16.3.6.2 Product Portfolio
- 16.3.6.3 Financials
- 16.3.6.4 SWOT Analysis
- 16.3.7 Novartis
- 16.3.7.1 Company Overview
- 16.3.7.2 Product Portfolio
- 16.3.7.3 Financials
- 16.3.7.4 SWOT Analysis
- 16.3.8 Pfizer
- 16.3.8.1 Company Overview
- 16.3.8.2 Product Portfolio
- 16.3.8.3 Financials
- 16.3.8.4 SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.